Sign in
Taking peoplePhase 1/2

Evaluating the Impact of Adjuvant Use of Beta Blockers on Clinical Outcomes in Patients With Traumatic Brain Injury

Key facts

Who runs it
Mansoura University
Where
Egypt2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 1/2
People taking part
100 people, planned
Started
20 Jan 2025
Planned end
Jun 2025
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • control
  • propranolol
  • Carvedilol
Record updated
2 April 2025

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Patients with moderate \& severe TBI detected on admission by CT scan and GCS score of ≤ 13 who either do not have any other injuries or only have associated minor injuries; Minor injuries are defined as presence of any of the following:
  • Mild intraperitoneal free fluid (IPFF) observed through abdominal ultrasound
  • mild lung contusion detected in the chest CT scan
  • hemothorax or pneumothorax present without accompanying symptoms of hypoxia, tachypnea, or respiratory distress
  • simple limb fractures

Who cannot take part

  • Patients on pre-injury beta-blocker therapy
  • TBI with GCS ≤ 13 with associated major injuries defined as the presence of any of the following:; Moderate \& marked IPFF requiring surgical intervention ( laparotomy ); moderate \& marked lung contusion, pneumothorax \& hemothorax with accompanying symptoms of hypoxia, tachypnea, lower limbs, or limb amputation; Compound fracture in the upper or lower limb; Open Faciomaxillary trauma
  • Patients with any bronchospastic conditions
  • Patients with active acute coronary syndrome
  • Patients with persistent shock (systemic blood pressure <100 mmHg, base deficit > 4, or oliguria , HR < 60 b/min ) after > one week of admission

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Propranolol primarily acts as a non-selective beta blocker, blocking both beta-1 and beta-2 adrenergic receptors, while carvedilol exhibits a broader spectrum of action by also blocking alpha-1 adrenergic receptors. The receptor blockade profile of a beta blocker can influence its physiological effects and potential therapeutic benefits in TBI. Therefore, the variation in receptor selectivity may result in differences in their impact on secondary brain injury processes and patient outcomes.

The 3 groups in the trial

  • Control ArmPlacebo, for comparison

    Treatment: control

  • propranololExisting treatment, for comparison
  • carvedilolExisting treatment, for comparison

    Carvid (carvedilol)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Fit questions
Built from NCT06836856, who can take part
Record updated
2 April 2025